FDA daily

FDA daily for Thursday, May 28, 2026

In this issue: 9 approvals and 31 device decisions. 1 item touches categories MedGrid carries, and it comes first.

For MedGrid's categories

Items in this issue that name a product category sold on MedGrid. Each links to its full FDA record; the chip opens that category's federal and state rules.

Drug and biologic approvals

FDA date:

On Thu, May 21 FDA approved 2 new applications (0 brand or biologic, 2 generic) and 7 supplements to existing ones.

  • LACOSAMIDE

    ADAPTIS · LACOSAMIDE

    ANDA220366Generic (ANDA)Discontinued
  • CLONAZEPAM

    RUBICON RESEARCH · CLONAZEPAM

    ANDA216988Generic (ANDA)Prescription
Browse drug and biologic approvals in FDA data →

Device clearances and approvals

FDA date:

FDA decided 19 510(k)s and 12 PMA decisions on Thu, May 14.

Browse device clearances and approvals in FDA data →

FDA did not answer for Drug recalls, Device recalls, Drug shortages, Labels, Food and supplement recalls while this issue was written; those sections will fill in on a later visit.

How the FDA daily is written

Every issue is written from FDA's public data (openFDA) and nothing else: the counts, names, firms and reasons are FDA's own. openFDA posts each kind of record on its own delay, so each section covers one FDA date and says which. Shortages cover yesterday; approvals, drug and device recalls, and food and supplement recalls cover a week ago; device clearances and label changes cover two weeks ago. Every FDA date appears in exactly one issue. Complete response letters appear the day after FDA publishes a batch.

Subscribe with any feed reader, or point an email tool at the RSS feed to send each issue as a newsletter. Search any drug, device or company across every FDA dataset in the FDA data explorer.

Read FDA's day. Stock your practice.

Join free with your NPI: wholesale pricing from verified vendors, with the FDA and state rules for each category one click away.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.